Literature DB >> 6400035

Studies with interferon-alpha in human tumors.

S Einhorn, H Strander.   

Abstract

Clinical trials with IFN-alpha, produced from buffy coats of leukocytes, have been going on at Radiumhemmet, Karolinska Hospital since 1969. In some of the benign and malignant tumor diseases studied, IFN has been shown to induce regressions. In the case of the benign tumor juvenile laryngeal papillomatosis, IFN has been shown to be superior to other treatment modalities. So far IFN has not been shown to be superior to conventional treatment in any of the malignant tumors studied.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6400035     DOI: 10.1007/BF02934980

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  8 in total

1.  Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells.

Authors:  K PAUCKER; K CANTELL; W HENLE
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

2.  Large-scale production of human leukocyte interferon containing 10(8) units per ml.

Authors:  K Cantell; S Hirvonen
Journal:  J Gen Virol       Date:  1978-06       Impact factor: 3.891

3.  Proliferation inhibitory effect of human alpha interferon on primary explants of Burkitt lymphoma: inverse relationship to patient survival.

Authors:  I Ernberg; S Einhorn; H Strander; G Klein
Journal:  Biomedicine       Date:  1981-11

4.  Interferon and laryngeal papillomatosis. The Iowa experience.

Authors:  B F McCabe; K F Clark
Journal:  Ann Otol Rhinol Laryngol       Date:  1983 Jan-Feb       Impact factor: 1.547

5.  Interferon therapy in juvenile laryngeal papillomatosis.

Authors:  S Haglund; P G Lundquist; K Cantell; H Strander
Journal:  Arch Otolaryngol       Date:  1981-06

6.  Human leukocyte interferon therapy for advanced ovarian carcinoma.

Authors:  N Einhorn; K Cantell; S Einhorn; H Strander
Journal:  Am J Clin Oncol       Date:  1982-04       Impact factor: 2.339

7.  Interferon therapy in myelomatosis.

Authors:  H Mellstedt; A Ahre; M Björkholm; G Holm; B Johansson; H Strander
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

8.  Leukocyte interferon in patients with juvenile laryngeal papillomatosis.

Authors:  H Goepfert; R B Sessions; J U Gutterman; A Cangir; W J Dichtel; M Sulek
Journal:  Ann Otol Rhinol Laryngol       Date:  1982 Jul-Aug       Impact factor: 1.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.